05508042 is referenced by 300 patents and cites 3 patents.

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e. every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.

Title
Controlled release oxycodone compositions
Application Number
800549
Publication Number
5508042
Application Date
June 6, 1995
Publication Date
April 16, 1996
Inventor
Robert F Kaiko
Weston
CT, US
John J Minogue
Mount Vernon
NY, US
Mark Chasin
Manalpan
NJ, US
Benjamin Oshlack
New York
NY, US
Agent
Steinberg Raskin & Davidson
Assignee
Euro Celtigue
LU
IPC
A61K 9/26
A61K 9/22
View Original Source